A New Diagnostic Approach for Myelodysplastic Neoplasms Using a Combination of Scores Based on Flow Cytometry and Automated Hematology Sysmex XN Analyzers

一种基于流式细胞术和Sysmex XN全自动血液分析仪评分相结合的骨髓增生异常肿瘤诊断新方法

阅读:1

Abstract

INTRODUCTION: The first-step in diagnosis of myelodysplastic neoplasms (MDS) is essentially based on bone marrow cytomorphology. However, cytomorphology of MDS is often a difficult exercise, subject to inter-operator variability. Our study aims to evaluate whether the combination of two dysplasia scores, the extended Ogata score and the MDS-CBC score, could improve the screening of MDS patients among patients with chronic cytopenia. METHODS: Extended Ogata score and MDS-CBC score have been measured on a retrospective cohort of 63 patients with a clinical suspicion of MDS based on the presence of cytopenia. Among these patients, 33 patients were diagnosed as MDS (MDS group) and 30 patients were diagnosed with another cause of cytopenia (non-MDS cytopenic control group). RESULTS: Our results show excellent performance of the combined scores in predicting MDS when the two scores are concordant: positive predictive value (PPV) = 96% and negative predictive value (NPV) = 92%. In comparison, in the same cohort, extended Ogata score alone showed a PPV = 90% and NPV = 79%, MDS-CBC score alone showed a PPV = 85% and NPV = 86%. CONCLUSION: For the first time, our results show that the combination of these two dysplasia scores constitutes a useful and rapid tool for the assessment of dysplasia associated with MDS. In the MDS diagnostic process, the use of combined scores could constitute a valuable tool to enable early strong prediction of MDS in cytopenic patients and to target patients who initially require additional genetic assays.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。